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INTRODUCTION
Early lesion studies in humans and translational preclinical
research using laboratory models as well as concomitant early
stimulation experiments, pharmacological treatment approaches
with L-DOPA in 1968 and the identification of circuit physiology
in the early 1980’s have led to the development of neuromodula-
tion techniques such as deep brain stimulation (DBS). In contrast
to medication-based approaches, knowledge gained from DBS as
both a probe and modulator of the underlying neural circuitry
resulted in a new way of describing and understanding (neuro)-
pathologies (top-down approach). Early stimulation experiments
such as those using non-human primates (Kringelbach et al.,
2010) were a glowing example of such development. However,
we still struggle with explaining the mechanisms of action of
DBS as Montgomery stated in his paper on logical pitfalls on
DBS results and mechanisms of action (Montgomery, 2012). 2012
marked the 25th anniversary of modern DBS. Although DBS is
being performed increasingly in centers worldwide, not much has
changed regarding the integration of new technological know-
how. This poses the distressing question of whether there is a
duty to overcome this lack of progress. The general picture of an
apparent arrested development does not at all light up when ana-
lyzing the approximately 40 years of emerging neurostimulation
technologies which were adapted into therapies by neurosurgeons
for different conditions during the 1970s (Gardner, 2013), besides
early stimulation experiments on patients e.g., by Robert Heath
and Jose Delgado. Compared to other technological advances in
different domains ranging from consumer electronics to medical
applications, the technological advance of DBS devices seems to
be almost nonexistent.
Furthermore, DBS is at a critical turning point which is
characterized by a subsequent collapse of the “last-resort” con-
notation DBS once had as a treatment for refractory disor-
ders. Indeed, beyond broadening indications to younger patients
with well-studied diseases, even questionable indications arise
(Hariz, 2012). Is it legitimate to use the same electrodes
and stimulation techniques in every region of the brain for
movement or psychiatric disorders? And isn’t it plausible that
local anatomy may need different hardware/software combina-
tions? Will old concepts of lesioning with new technologies,
e.g., high-intensity focused ultrasound, replace DBS in some
domains (Lipsman et al., 2013)? Is it possible that genetic
and cell culture technologies could overrun the “gold stan-
dard” DBS for Parkinson’s disease in the future (Lindvall,
2013)?
TECHNOLOGICAL DEVELOPMENTS: DIFFERENT
CONTEXTS—SAME PATTERNS?
Figure 1 depicts some of the technological advances that have
had applications both inside and outside the medical domain. For
our purpose it is sufficient to state that the driving factors for
technological evolution and innovation are the following:
1. reduction of size dimensions
2. increase of complexity and variability of tasks which can be
executed
Lewis H. Morgan’s stage model of social evolution involves
the analysis of technological milestones and declares technological
progress to be the primary factor driving the development of
human civilization. On the basis of this model, there is the
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FIGURE 1 | Illustrative examples of technological developments in the
past 25 years which refer to miniaturization aspects and
ground-breaking change of technological complexity. Wheel chair bound
patients could in the meanwhile benefit from the possibility of full
mobilization due to an exoskeleton device (adapted from: http://www.
medicalspro.com/manual_wheelchair.php, http://www.designboom.
com/technology/elegs-exoskeleton-by-berkeley-bionics/). External devices
of cochlear implants have become remarkably smaller (adapted from:
http://www.enttoday.org/details/article/4550891/History_of_the_Cochlear_
Implant.html, http://www.audiology.org.nz/Userfiles/Image/implant6_lge.jpg).
Television, Walkman and Mobile Phone have become a single, extremely
sophisticated multifunctional tool with wireless connections to other
technical devices and integrating Internet (Smart-Phone). (adapted from:
http://www.radiomuseum.org/r/waltham2_tele_star_4004.html,
http://www.telegraph.co.uk/technology/5733286/Sony-Walkman-in-pictures.
html?image=4, http://www.webdesignerdepot.com/2009/05/the-evolution-of-
cell-phone-design-between-1983-2009/; IPG & mobile phone images used by
courtesy of owner).
question of how to interpret our current evolutionary stage by
focusing on DBS device advances (see Figure 1). Have we pro-
gressed beyond Morgan’s savagery stage?
Pragmatically we think it is fair to say that in the con-
text of DBS, neither (1) nor (2) have yet been satisfied (also
see Figure 1 for a direct, schematized visual comparison).
The possibility of spatial steering brain stimulation (Martens
et al., 2011; Hariz, 2014) or adaptive DBS (Little et al., 2014)
barely rises at the horizon. Furthermore, settings are pre-
determined per electrode site and can be changed only in a
very restricted way due to the missing feedback path (Eberle
et al., 2011). Also it appears as if technological trends from
neighboring disciplines (i.e., “technology-transfer” (Morlacchi
and Nelson, 2011)), such as the gravitation-field sensor sys-
tem in the context of spinal cord stimulation or nano-
technology have not in the least been adopted by the DBS
industry. Currently, greater emphasis is put on the issue of
MRI safety of DBS implants due to diagnostic highfield-MRI
(Paek et al., 2013), which is increasingly being used in clinical
work.
A THOUGHT-PROVOKING PIECE OF SURGICAL EVIDENCE
Results of randomized controlled trials have just recently been
published without major differences regarding outcome of STN-
DBS vs. GPi-DBS (Weaver et al., 2012; Odekerken et al., 2013).
Figure 2 depicts the desperate search and use of the newest
technology available for treating a patient with Parkinson’s
disease. Both physician and patient were willing to try the
best treatment possible for alleviating the symptoms of this
disabling disease. The X-ray images were acquired in 2009
before exchange of the implantable pulse generators (IPGs)
connected to the STN (subthalamic nucleus) electrodes. One
could speculate that a change to a more sophisticated tech-
nological system in GPi (globus pallidus internus) stimula-
tion could have served the purpose of inducing a therapeutic
effect without undergoing additive stereotactic surgery. Those
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FIGURE 2 | A unique witness of DBS history. Bilateral monopolar
electrodes were implanted within the internal globus pallidus (GPi) in
1998 in a patient having suffered from typical Parkinson’s disease since
1984. Predominant disabling dyskinesia improved significantly afterwards
(black arrows: more lateral in (A) and more anterior in (B)). Because of
re-emerging motor fluctuations without further optimization possibilities
of the monopolar GPi electrodes (probably side effects), bilateral
quadripolar electrodes (white arrows) were then implanted within the
STN in 2001 accounting finally for four intracerebral electrodes and four
pulse generators (C,D). The patient profited for around 3 years before
developing late stage symptoms, like frequent falls, voice alteration,
On-dystonia in her lower extremities and cognitive decline. The two GPi
generators were explanted in 2009 as additional beneficial effects were
not seen.
images unmask the hopeful will to change treatment in regard
to hardware and target without having understood the fail-
ure of the monopolar GPi stimulation in this patient. The
transition from mono- to quadripolar electrodes still remains
the maximum of technological progress today. In daily clin-
ical work, there is a subliminal frustration on the imbal-
ance of having more than 10,000 programming possibilities,
e.g., frequency, pulse width and amplitude, without being able
to optimize stimulation for the individual patient (Volkmann
et al., 2006; Ricchi et al., 2012). Instead, expert recom-
mendations remain the evidential basis of setting param-
eters. Regarding multiple joint prostheses and four IPG’s,
this patient has reached nearly the limit of medical implant
costs.
TECHNOLOGICAL CONSIDERATIONS
The recent advances of increased magnetic field strength observed
in MRI-system technology should ultimately lead to an improve-
ment in the accuracy of electrode positioning. This is particularly
important given the high interindividual anatomical variability of
structures such as the STN, because personalized, image-based
targeting provides higher accuracy than atlas-oriented targeting
(Ashkan et al., 2007). Moreover, Zaidel et al. (2010) showed
optimal clinical efficacy by determining local electrophysiolog-
ical parameters characterized by increased β-oscillatory activ-
ity on multi-unit recordings rather than by pure anatomical
analysis.
Today, the impossibility of detecting specific alterations in
underlying brain activity depending on the condition being
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treated is a major limitation. Do we pay tribute to extremely
complicated homeostasis patterns of a billion years of evolution,
e.g., circadian neuroendocrine interaction and electrochemical
networks? Currently, IPGs can be programmed through
modifying frequency, pulse width, current output (amplitude),
interleaved mode (Baumann et al., 2012) between contacts and
limited possibilities of groups/cycling modes. In routine clinical
practice, the physician usually takes “standard” programs known
from the literature. In case of side effects of medication and
stimulation interaction in the variable disease patterns, “trial
and error” within thousands of programming possibilities can be
frustrating, extremely time-consuming and may require hospital-
ization of “difficult” patients (Volkmann et al., 2006; Hariz, 2012).
Steering the electrical current and granting MRI compatibility
are recent and important developments to solve the problem of
side effects, energy consumption and harmless hardware-tissue
interaction (Hariz, 2014). Given that the brain uses dual-mode
communication and feedback strategies, an effective treatment
needs to detect and return both real-time monitoring of chemical
neurotransmitter release levels as well as electrical firing patterns
(Rosin et al., 2011)—in other words, closed loop self-regulatory
systems (Grahn et al., 2014). One of these systems is currently
under investigation at multiple centers worldwide without any
information, yet on future efficacy or availability. The advances of
real-time, instantaneous neurochemical and electrophysiological
sensing combined with feedback-guided anticipatory adjustment
and sophisticated electrode (lead) design (Arcot Desai et al., 2014;
Hariz, 2014; Kent and Grill, 2014) could lead to a fully integrated,
small and high precision, low-power circuit supporting a wireless
neuromonitoring and neuromodulation system (Shah et al.,
2010). Hence, avoiding thick, unlabeled cables and clumpy
IPGs would reduce acute and long-term morbidity as hardware
complications still remain frequent adverse events in DBS surgery
in many centers (Hamani and Lozano, 2006).
Additionally, there is a lack of monitoring and integrating
disease symptoms together with general health and activity status
of the patients. There is no automatic or remote report system,
e.g., of “red flags” of symptoms or hardware-related problems, not
even for precise battery life duration.
We argue therefore that the time has come to focus on advanc-
ing the DBS system in terms of technological properties to better
meet individual patient needs, leading to more effective symptom
control, improved patient quality of life and reduced healthcare
costs.
Given the importance of DBS, the lack of biomarkers for many
complex conditions and the associated need for a critical and
objective pre- and post-DBS therapy evaluation, we argue that
we should emphasize improving means for a holistic evaluation
of patient’s clinical status. As Gardner (2013) brought to the
fore the decisive role of the invention of a (synthetic) UPDRS
rating scale for the emergence of DBS, we also have a duty to
critically question whether the creation of such an objective
numerical variable in order to have a basis for comparing pre-and
post-stimulation effects fully embraces the patient and results in
improvement of symptoms. Gardner further states: “Thus while
such a tool may generate the necessary “objective evidence” to
legitimate the intervention and enable device manufacturers to
market their device, it may not be capturing clinical changes that
are meaningful to patients and their families” (Gardner, 2013).
Thus, quantified rating scale scores have to be complemented by
qualitative measures (Bagby et al., 2004).
ECONOMIC CONSIDERATIONS
Of course, medical products are under stricter regulatory pro-
cesses than consumer goods, and doctors or patients are not
simple consumers. To the best of our knowledge, one sin-
gle company held the monopoly for DBS application systems
for almost 20 years. Even after the introduction of two other
key companies, besides newly emerging vendors highlighted in
a recent market study (Global Deep Brain Stimulator Market
2012–2016),1 there was no ground-breaking new technological
development. Not more than minor changes in programming
possibilities, lead and fixation design, and battery properties
have occurred. This is problematic since we find ourselves in
a context of severe diseases which depend on innovative treat-
ment options. The lack of favorable (see Hashmi, 2013) com-
petition for product-innovation for developing safer and more
effective neuromodulation techniques stands in marked contrast
to the situation of other technological domains outside the
medical field, such as the mobile phone or automobile indus-
try. Here we face a highly dynamic progression of consumer-
oriented new developments. In other, more competitive domains
within medicine, such as orthopaedic surgery/applications, a
more innovative landscape can be observed. A lack of com-
petition may be one reason why we are confronted with a
shortage of technological progression in the DBS field. By
looking at the economic literature, and by keeping in mind
that the health-economic sector is different, one could argue
that more product market competition can under certain cir-
cumstances increase product-innovation (Aghion et al., 1999,
2009; Aghion and Griffith, 2005; Hashmi, 2013; Roper et al.,
2013).
In the DBS context, it is unclear why we do not face a
pronounced conflict between attending physicians and industry
regarding differing claims. Possibly there is not enough demand
(supply-and-demand situation) verbalized by the medical estab-
lishment which could explain a lack of innovation potentially
due to daily work-intensity and time pressure, regulatory hurdles,
investment return considerations, installed base effects, a lack of
knowledge-transfer from basic science to users in clinic or a low
level of sensibility to grasp the responsibility to strive for more
benefit to the patient.
One could potentially identify a subliminal tendency towards
investing in other indications, thereby increasing the number of
implants instead of improving quality.
ETHICAL CONSIDERATIONS
We argue that there is a multidimensional obligation to pro-
mote innovation which should include all agents involved in
the process of helping patients in need. We restrict ourselves to
the two domains already highlighted above, namely the medical
community and the medical device industry. Those domains
1http://www.researchandmarkets.com/reports/2538063/
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should both promote innovation since they have complementary
rather than competing goals. In the following, we focus briefly on
the medical community on the one hand and more extensively
by the use of a framework-based argumentation on the medical
device industry on the other.
It appears that the medical establishment has failed to build
on the dynamic treatment breakthroughs of the past due to
overconfidence and a lack of vision. The initial clinical efficacy
in resolving some symptoms obscured the once broadly heralded,
noble aspirations of gaining deeper understanding of DBS. Even
though the subsequent unraveling of side effects could have driven
clinicians to obtain deeper scientific knowledge as well as to
optimize treatment, this unfortunately was not pursued with the
required vigor.
We believe that it is therefore time to include some ethical
reflection in the debate. One could argue that industry and the
medical community both have a duty to invest more in technolog-
ical advances by concomitantly ensuring that treatments are safe
and effective (Hofbauer et al., 2013). Generally more emphasis
should be put on basic scientific advances (Hamani and Temel,
2012), thereby reaching a level of development which in the end
will, as a manifestation of a sensitive pleading for the centrality of
patients, help those most in need. Also the question of an ethical
responsibility to strive for the best and latest technology for the
treatment of one of our most sheltered organs, our brain, should
be discussed.
An ethical framework is needed to make this normative
claim more transparent and more systematically structured. We
believe that interposing some normative considerations may
have beneficial effects in terms of sensitizing the community.
This could be a starting point for an eclectic and multifaceted
normative discussion. Moreover, such a framework is neces-
sary to guide innovation within the field of DBS. In order to
make a normative claim such as the duty or responsibility to
promote technological advance, one may pursue this idea by
making use of an already established ethical framework such as
the one provided by Beauchamp and Childress (2013), thereby
analyzing the effects of technological development on primary
ethically relevant parameters. We have chosen this particular
framework as a starting point for normative reflection because
of its established and wide use within the clinical context. It
incorporates two core bioethical principles, namely “primum
non nocere” (“First, Do No Harm”), reflected in the duty of
nonmaleficence and beneficence, which could be described as
the duty to promote the good of others. Regarding the need
for and further development of neuromodulating devices, the
principle of beneficence is especially ethically relevant. We believe
that it is important to incorporate the values reflected in these
principles into the context of industry. For one could argue
that patients’ well-being may be positively affected by the imple-
mentation of technological innovation. Beneficence and non-
maleficence apply not only to the medical domain but also to
that of industry and need to be balanced with the economics
of the medical device industry and the need for companies to
survive.
The application of these principles means that the ethical
justification of any technological advance in neuromodulation
depends on whether it is beneficial for patients and improves their
well-being. As stated above, we argue that ethical considerations
require that all stakeholders should be involved in the discussion.
Accordingly, a duty to promote technological advance should
not be restricted to the medical domain but also should be
radially projected in order to positively affect all agents involved.
If we genuinely care for the patient’s wellbeing, then the prin-
ciple of beneficence should not only apply to the medical con-
text but should have the power to transcend contextual barri-
ers.
The goals of technological innovation and patient welfare
should be complementary. Device-makers funding DBS clinical
trials have an obvious interest in proving that their product can
modulate neural circuits. Yet this has the potential to create a
conflict of interest for researchers wanting to know how DBS
affects the brain and mind of subjects if the manufacturer influ-
ences the design of the trial and the interpretation of the results.
The potential for conflict is greater when the researcher has
invested in such a company. Policies must be in place to prevent
or at least reduce the probability of this conflict by ensuring
the scientific integrity of clinical trials and that testing DBS is
consistent with the interests of patients in experiencing symptom
relief and improved quality of life. Ultimately, patient welfare
should be the main impetus of any duty of innovation to produce
more advanced neuromodulating devices (Fins and Schiff, 2010;
Fins et al., 2011).
In our discussion of beneficence, we identified one pertinent
principle which we thought to be easily accessible as well as used
in practice. But because it is beyond the scope of this paper,
we refrain from elaborating on the critical steps of balancing
and weighing different values against each other. There might
of course be other issues that potentially outweigh a duty of
innovation under certain circumstances.
Moreover, there is a need for interdisciplinary exchange
between and among representatives of patient organizations,
industry, basic science, medicine and ethics in order to shape
the future of DBS. A recent interdisciplinary, international forum
(“brains in dialogue”, BID project)2 trying to foster this dialogue
was unfortunately closed.
CONCLUSION
DBS is an established therapeutic intervention and has recently
provided hope for many patient groups including but not limited
to movement disorders. Significant innovation in the field of
DBS has mainly been reflected by introducing novel indications,
rather than advanced technologies. We still lack a mechanistic
explanation of the underlying processes involved. In turn, one
has to acknowledge that the limited understanding of brain func-
tions (bottom-up approach) poses a critical barrier to innova-
tion. Deeper insight is crucial to further advance DBS systems
towards intelligent, self-regulating closed-loop devices in combi-
nation with miniaturization and MRI-compatibility of hardware,
sophisticated electrodes and programming possibilities. Further-
more, especially in the case of new indications, international joint
2http://www.neuromedia.eu/NewsData.aspx?IdNews=1325&IdType=296&
type=Actual
Frontiers in Human Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 730 | 5
Ineichen et al. A critical reflection of DBS-development
meetings should include preclinical translational researchers as
well as ethicists, recognized patient organizations, engineers and
healthcare providers in neurology, neurosurgery and psychiatry
for the translation of technological advances in order to create
consensus of future directions of development and to improve
outcomes of established indications. This consensus could be
addressed to regulatory bodies for a representative impact. Finally,
there is a greater need for sensitivity to the ethical duty to
actively promote and demand technological advancement in
neuromodulation.
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